


PRODUCT INFORMATION



ATR-258

Item No. 45371

CAS Registry No.: 2301983-88-8
Formal Name: α R-[[[(1,1-dimethylethyl)amino]methyl]-5-fluoro-3-pyridinemethanol
MF: C₁₁H₁₇FN₂O
FW: 212.3
Purity: \geq 98%
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ATR-258 is supplied as a solid. A stock solution may be made by dissolving the ATR-258 in the solvent of choice, which should be purged with an inert gas. ATR-258 is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of ATR-258 can be prepared by directly dissolving the solid in aqueous buffers. ATR-258 is sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

ATR-258 is a GRK-biased agonist of the β_2 -adrenergic receptor (β_2 -AR).¹ It binds to the orthosteric site on β_2 -AR and mediates glucose uptake dependent on G protein-coupled receptor kinase 2 (GRK2) with low $G\alpha_s$ -dependent cAMP generation in a phenotypic screen. ATR-258 (10 μ M) increases glucose uptake in L6 cells that endogenously express β_2 -AR, an effect that can be blocked by the β_2 -AR antagonist ICI 118551 (Item No. 15591) or the mTORC2 inhibitor JR-AB2-011. Oral administration of ATR-258 (0.3 mg/kg) improves glucose tolerance, reduces fat mass, and increases lean mass in diet-induced obese (DIO) mice without increasing heart weight. ATR-258 in combination with liraglutide (Item No. 24727) reduces fat mass without reducing lean mass in DIO mice.

Reference

1. Motso, A., Pelcman, B., Kalinovich, A., *et al.* GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. *Cell* **188**(19), 5142-5156 (2025).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/07/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM